WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting clinical research, today announced that it has filed, on Friday, September 11, 2026, a bid to acquire the business operations and assets of IntegraGen, a company specializing in genomic analysis of nucleic acids, particu…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.